Skip to main content

iwCLL 2025 Main banner

iwCLL X / Twitter

124 Views

Poster

1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Primary Author(s)

DL

David Lavie, MD

Hadassah Medical Center
Jerusalem, Yerushalayim, Israel

Co-Author(s)

MO

Muhit Ozcan, MD, PhD

Ankara University School of Medicine
Ankara, Ankara, Turkey
Arvind Chaudhry, MD, PhD

Director
Summit Cancer Centers
Spokane Valley, Washington, United States
XZ

Xuan Zhou, PhD, MS

Merck & Co., Inc.
Rahway, New Jersey, United States
IP

Ima Paydar, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Mohammed Z. Farooqui, Phd

Executive Director
Merck & Co., Inc.
Rahway, New Jersey, United States

Co-Author / Presenter(s)

Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy